利妥昔单抗和静脉注射免疫球蛋白治疗复发性感染后性眼阵挛-肌阵挛综合征

Rituximab and intravenous immunoglobulins for relapsing postinfectious opsoclonus-myoclonus syndrome.

作者信息

Leen Wilhelmina G, Weemaes Corry M, Verbeek Marcel M, Willemsen Michèl A, Rotteveel Jan J

机构信息

Department of Pediatric Neurology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands.

出版信息

Pediatr Neurol. 2008 Sep;39(3):213-7. doi: 10.1016/j.pediatrneurol.2008.05.015.

DOI:10.1016/j.pediatrneurol.2008.05.015

PMID:18725071

Abstract

We describe 2 children with postinfectious opsoclonus-myoclonus syndrome. Although the patients initially responded to monotherapy with methylprednisolone, intravenous immunoglobulins, or rituximab, they manifested persistent neurologic deficits and relapsing signs. Treatment with rituximab in combination with intravenous immunoglobulin, however, resulted in significant longterm clinical improvement.

摘要

我们描述了2例感染后性眼阵挛-肌阵挛综合征患儿。尽管这两名患者最初对甲泼尼龙、静脉注射免疫球蛋白或利妥昔单抗单药治疗有反应，但他们仍表现出持续的神经功能缺损和复发体征。然而，利妥昔单抗联合静脉注射免疫球蛋白治疗带来了显著的长期临床改善。